Every year, the American healthcare system writes a check it doesn’t talk about. Estimates of fraud, waste, and abuse (FWA) in U.S. healthcare spending range from roughly 3 percent on the conservative end to as much as 10 percent or more, depending on methodology and payer type. Applied against a healthcare economy north of $5.9 trillion, even the low end of that range translates into well over $100 billion a year, and industry estimates push the figure up to $300 billion. And the detection rates of fraud alone, not to mention all improper payments, is noted to be in many cases as low as 10% or even 1%. These aren’t abstractions. They are premiums, deductibles, and taxpayer dollars quietly redirected away from the people the system exists to serve.
What makes FWA different from other cost drivers is that it is, in principle, addressable. We can’t legislate away the price of a new oncology drug or the demographic reality of an aging population. But a duplicate claim, an upcoded procedure, an unbundled lab panel, or a medically unnecessary device order is, by definition, a cost that shouldn’t have happened. Every dollar recovered or prevented is a dollar that didn’t need to be spent, making FWA reduction one of the few truly non-zero-sum levers available to bend the cost curve.
Why the problem persists despite decades of attention
Healthcare fraud, waste, and abuse training has been mandatory for Medicare Advantage and Part D plan sponsors for years. CMS (Centers for Medicare & Medicaid Services) has steadily increased program integrity investment, and the most recent fiscal year delivered record results: total Medicare program integrity savings reportedly grew sharply year-over-year, with a return on investment exceeding 22-to-1 — among the highest ever recorded. That’s encouraging, and it proves the underlying thesis: when detection improves, recovery and avoidance scale with it.
But the persistence of the problem despite enforcement gains tells us something. Recovery after the fact, the “pay and chase” model, has a structural ceiling. Industry data suggests less than half a percent of total FWA losses are ever recovered once a claim has been paid. The economics favor getting it right before the dollar leaves the building, not chasing it afterward through audits, appeals, and litigation that themselves consume administrative resources.
This is true across every line of business, not just Medicare. Medicaid, Medigap supplemental coverage, and ERISA self-funded employer plans each carry distinct vulnerabilities — different coding patterns, different oversight structures, different population risk profiles — but they share a common root cause: claims data that is reviewed too late, too narrowly, or with too little context to catch the pattern before payment.
The affordability connection that gets lost in the conversation
Policy conversations about healthcare affordability tend to gravitate toward premium subsidies, drug pricing reform, or provider consolidation. Those matter. But they largely treat the size of the bill as fixed and argue about who pays it. FWA reduction works on the bill itself.
Consider the mechanics: a self-funded employer plan that improperly pays even a few percentage points more than it should on claims doesn’t just lose that money — it bakes that inflated baseline into next year’s premium calculations, into stop-loss insurance pricing, and into the employee contribution levels HR teams negotiate every fall. A Medicare Advantage plan absorbing avoidable improper payments faces the same dynamic through risk-adjustment and bid pressure. The waste compounds. Conversely, when a payer can demonstrably show, not estimate, but show, with auditable evidence, that it is catching FWA at a meaningfully higher rate than before, that capability becomes a lever it can use in actual cost negotiations, not just a compliance talking point.
This is also where the affordability argument becomes a quality argument. Waste isn’t only financial. Unnecessary procedures, duplicate imaging, and inappropriate utilization carry clinical risk for patients, independent of cost. Reducing FWA and improving care quality are not competing priorities; in claims data, they are frequently the same signal.
What better identification actually requires
The technology conversation in this space has matured. Rules-based detection — essentially sophisticated query logic against claims data — has been the industry workhorse for years and still catches real fraud. But rules only catch what they’re written to look for, and bad actors adapt faster than rule libraries get updated. The next layer of capability uses pattern recognition across larger, more varied datasets to surface anomalies that no static rule was written to anticipate: a provider’s billing pattern that’s subtly out of family with peers, a referral network with unusual density, a utilization curve that doesn’t match a diagnosis.
The honest caveat is that more sophisticated detection isn’t automatically better detection. It has to be explainable to a human reviewer, defensible in an appeal, and calibrated to the distinct risk patterns of Medicare Advantage, Medicaid, and self-funded ERISA plans, because those populations and incentive structures genuinely differ. A model tuned on one doesn’t transfer cleanly to another without real domain expertise built into how it’s trained and validated.
The bigger picture
None of this suggests technology alone solves healthcare affordability. But FWA reduction is one of the rare areas where better tooling, better data discipline, and better tracking produce savings that are real, measurable, and don’t require anyone to receive less care or pay a higher price for the same care. In an industry where most cost conversations are zero-sum, that’s worth taking seriously, and worth building for deliberately, rather than treating as a compliance afterthought.
The dollars are already being spent. The only question is whether we’re willing to see where they’re going.
Sources:
- Centers for Medicare & Medicaid Services, “Crushing Fraud, Waste, & Abuse,” gov/fraud(accessed June 2026) — FY2025 Medicare program integrity savings and ROI figures
- Sparrow MK. They Stole Your Umbrella: Why Healthcare Professionals Should Support Stronger Fraud Controls. Mo Med. 2026 Jan-Feb;123(1):4-11. PMID: 41742920; PMCID: PMC12931588
- Milliman, “How effective claims auditing can save healthcare dollars lost to fraud, waste, and abuse,” com— 3% conservative / 10%+ ($300B+) FWA estimate, citing the National Health Care Anti-Fraud Association (NHCAA), “The Challenge of Health Care Fraud” (2025)
- Managed Healthcare Executive, “Fraud, Waste and Abuse in Healthcare Claims and Who It’s Affecting,” com— $250B–$800B annual FWA range; commentary from Clay Wilemon, CEO of 4L Data Intelligence
- Managed Healthcare Executive, “What Fraud and Abuse Has Cost Healthcare, How & How Much AI Can Save the Industry From It,” com— Blue Cross Blue Shield of Michigan $230B estimate; $700–800B high-end estimate
- GoInvo, “Fraud, Waste, and Abuse in Healthcare,” com— $1.32T (30% of spend) total FWA estimate; ~0.14% post-payment recovery rate, citing HHS/DOJ Health Care Fraud and Abuse Control (HCFAC) Program Annual Report
- Healthesystems, “Triple Threat: Healthcare Fraud, Waste and Abuse in Workers’ Comp,” com— $100–300B in cross-payer fraud estimate; ~25% of healthcare spend considered wasteful; workers’ comp-specific fraud figures
- Fraud, Waste and Abuse Information (Health Plan of Nevada / Sierra Health and Life), com— 3–10% of total healthcare spending estimate; CMS Medicare Advantage/Part D training requirement context